INTRODUCTION AND OBJECTIVES: There is clinical equipoise as to the most cost effective approach for the treatment of lower pole stones between 10-20mm. We aimed to assess the clinical features, outcomes, complications, and cost-effectiveness of ambulatory SWL, FURS and PCNL in the treatment of lower pole (LP) stones (10-20mm) in a large tertiary referral stone centre.
INTRODUCTION AND OBJECTIVES: There is clinical equipoise as to the most cost effective approach for the treatment of lower pole stones between 10-20mm. We aimed to assess the clinical features, outcomes, complications, and cost-effectiveness of ambulatory SWL, FURS and PCNL in the treatment of lower pole (LP) stones (10-20mm) in a large tertiary referral stone centre.
METHODS: Consecutive patients treated for solitary LP stones (10-20mm) between 2008-13 were identified from a prospective database. Ambulatory SWL under sedo-analgesia (diclofenac +/-alfentanyl) was used as primary treatment in all cases (following a stone MDT assessment), with FURS and PCNL reserved for SWL contraindications, failure or patient choice. "Success" was defined as stone free and/or clinically insignificant stone fragments (¼3mm) at 1 and 3 months follow-up. Effect of anatomy on SWL success was determined from using CT images and regression analysis. Average cost per treatment modality (including additional second-line treatments) was calculated using the NHS England 2014/15 National Tariff HRG codes.
RESULTS: 225 patients were included (mean age 54.9; median stone size 12mm). 198 (88%), 21 (9.3%) and 6 (2.7%) patients underwent SWL, FURS and PCNL as primary treatments respectively; for median stone sizes of 12mm, 12mm, and 20mm. Overall success rates were 82.8%, 76.1% and 66.7% respectively (p < 0.05). 63% of patients undergoing primary SWL were successfully treated after one session. Anatomical analysis determined infundibulopelvic angle and infundibular length to be significantly different in patients successfully treated with SWL (p ¼ 0.04. SWL was performed with superior length of stay and complication rates compared to FURS or PCNL (p<05), and with a low auxiliary treatment rate (7%). SWL was significantly more cost-effective (mean £751/patient) than FURS (mean £1261) or PCNL (mean £2658) (p < 0.01).
CONCLUSIONS: SWL is a cost-effective, and efficacious primary treatment for patients with solitary LP stones (10-20mm). The majority of patients can be successfully treated with primary SWL in a dedicated stone centre, with the benefits of a short length of stay, low complication and auxiliary treatment rates, and without the need for general anaesthesia. The referral of such patients to high-volume lithotripsy centres with demonstrable outcomes should be given due consideration.
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MP62-19 CROSS VALIDATION OF A PREDICTIVE ANALYTIC MODEL WHICH PREDICTS SUCCESS AND COMPLICATIONS OF SHOCKWAVE LITHOTRIPSY
Blake Hamilton*, Salt Lake City, UT; Ryan Seltzer, Donald Gleason, Tucson, AZ; Stephen Nakada, Madison, WI; Glenn Gerber, Chicago, IL INTRODUCTION AND OBJECTIVES: Shockwave lithotripsy (SWL) is a primary treatment for nephrolithiasis that has been used widely for the past 3 decades. Recently, this technology has come under fire because of declining outcomes in the face of improving alternative technologies. Multiple authors have described pre-operative parameters that improve the success of SWL, including stone size, location, density, and skin-to-stone distance. Using these and other parameters, we present a predictive analytic model to help urologists select the most effective treatment modality with the highest likelihood of success and lowest likelihood of complication.
METHODS: We performed a random 70/30 split of 7,000 SWL treatment records for renal and ureteral stones from 2010-2016 to train and validate a generalized linear mixed model (GLMM) using statistical software (PROC GLIMMIX in SAS 9.4). This model uses 9 parameters: stone size, Hounsfield Units (HU), body mass index (BMI), stone location, anesthesia type, SWL machine type, anticoagulant use, age, and gender to predict treatment success, defined as stone free or fragments ¼ 4mm, and to predict treatment complications. Actual treatment success and complications were obtained from self-reported physician follow-up surveys tied to the original SWL treatment record. Both treatment and follow-up data are housed in The Stone Disease Registry.
RESULTS: The training model was significantly related to treatment success, Likelihood Ratio (LR) Chi-square ¼ 1136.02, p < .0001, Area under the curve (AUC) ¼ .82. This model was in turn a good predictor of success in the validation dataset, AUC ¼ .81. The training model was also significantly related to complications, Likelihood Ratio Chi-square ¼ 538.75, p < .0001, AUC ¼ .91. This model was a fair predictor of complication rate in the validation dataset, AUC ¼ .77.
CONCLUSIONS: This novel predictive analytic model provides accurate prediction of treatment success and complications for SWL. Given the robust model fit to the validation data, we conclude that this model will be useful in prospectively predicting success for the treatment of urinary stones with SWL. This has the potential to assist urologists in prospectively making evidence-based decisions on which treatment modality will be most effective in maximizing success and minimizing complications and costs for treatment of urinary stones.
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